TY - JOUR
T1 - Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer
AU - Figoli, Franco
AU - Veronesi, Andrea
AU - Ardizzoni, Andrea
AU - Canobbio, Luciano
AU - Bruschi, Gioia
AU - Mazza, Francesco
AU - Zagonel, Vittorina
AU - Lo Re, Giovanni
AU - Rosso, Riccardo
AU - Monfardini, Silvio
PY - 1988
Y1 - 1988
N2 - Twenty-seven evaluable patients with small cell lung cancer (SCLC) resistant to, or relapsed after induction combination chemotherapy (CT) were treated with etoposide (VPJ6) plus cisplatin (DDP). Previous treatment was: alternating CT with cyclophosphamide (C), adriamycin (A), methotrexate (M), procarbazine (P) (CAMP)/VP16, BCNU (B), hexamethylmelamine (H) (VP16BH) in 16 patients; C, A, vincristine (CAV) in 6 patients; C, A, and VP16 (CAVP16) in 5 patients. We observed 2 (7% complete responses (CR) and 9 (33% partial responses (PR). Duration of CRs was 8 and 14 weeks, respectively. PRs lasted a median of 22 weeks (range 16-44). Seven of 21 (33% patients previously treated with VP16 responded to DDP plus VP16 (D-V). These results confirm D-V regimen as active in SCLC patients even when heavily pretreated. Our 33 % response in patients who had VP16 in their induction treatment regimen provides further evidence of an important potentiating effect of DDP, as reported in animal system.
AB - Twenty-seven evaluable patients with small cell lung cancer (SCLC) resistant to, or relapsed after induction combination chemotherapy (CT) were treated with etoposide (VPJ6) plus cisplatin (DDP). Previous treatment was: alternating CT with cyclophosphamide (C), adriamycin (A), methotrexate (M), procarbazine (P) (CAMP)/VP16, BCNU (B), hexamethylmelamine (H) (VP16BH) in 16 patients; C, A, vincristine (CAV) in 6 patients; C, A, and VP16 (CAVP16) in 5 patients. We observed 2 (7% complete responses (CR) and 9 (33% partial responses (PR). Duration of CRs was 8 and 14 weeks, respectively. PRs lasted a median of 22 weeks (range 16-44). Seven of 21 (33% patients previously treated with VP16 responded to DDP plus VP16 (D-V). These results confirm D-V regimen as active in SCLC patients even when heavily pretreated. Our 33 % response in patients who had VP16 in their induction treatment regimen provides further evidence of an important potentiating effect of DDP, as reported in animal system.
UR - http://www.scopus.com/inward/record.url?scp=0023912834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023912834&partnerID=8YFLogxK
U2 - 10.3109/07357908809077023
DO - 10.3109/07357908809077023
M3 - Article
C2 - 2835127
AN - SCOPUS:0023912834
VL - 6
SP - 1
EP - 5
JO - Cancer Investigation
JF - Cancer Investigation
SN - 0735-7907
IS - 1
ER -